Rewrite request acknowledged. The goal is to rephrase the supplied content in clear, unique English while preserving meaning, key details, and tone. The revised version will expand slightly where appropriate, maintain a friendly yet professional voice, and introduce a bold opening hook to engage readers. It will also highlight potential controversy or differing opinions where relevant and end with a provocative question to invite discussion.
But here’s where it gets interesting: this piece centers on a new FDA-approved biosimilar presentation of OMLYCLO®, a drug linked to asthma, CRSwNP, IgE-mediated food allergies, and CSU. The stakes involve dosing flexibility, patient comfort, and ongoing debates about biosimilar interchangeability, access, and cost.
Rewritten content:
Bold opening: A new 300 mg dose of OMLYCLO® has just joined the lineup as the first and only FDA-designated interchangeable biosimilar to XOLAIR®, signaling a potentially meaningful shift in how allergic diseases are treated in the U.S.
Celltrion, Inc. announced that the U.S. FDA approved OMLYCLO® (omalizumab-igec) at 300 mg/2 mL in a single-use prefilled syringe for subcutaneous injection. This addition expands dosing options and supports personalized treatment strategies for patients with certain allergic conditions. In the United States, OMLYCLO® will be marketed exclusively by Celltrion USA, Inc.
Background and scope: Earlier in March 2025, the FDA approved OMLYCLO® in 75 mg/0.5 mL and 150 mg/mL presentations for subcutaneous injection. These forms are indicated for moderate to severe persistent asthma, chronic rhinosinusitis with nasal polyps (CRSwNP), IgE-mediated food allergy, and chronic spontaneous urticaria (CSU).
Executive quotes and intent: Dr. Juby Jacob-Nara, Senior Vice President and Chief Medical Officer at Celltrion USA, stated that adding the 300 mg option broadens treatment choices, reduces injection frequency, and lowers overall treatment burden for patients with these allergic conditions. Thomas Nusbickel, Chief Commercial Officer at Celltrion USA, emphasized the company’s commitment to expanding access to biologic therapies in the U.S. and supporting physicians with flexible, high-quality options.
Product overview: OMLYCLO® (omalizumab-igec) is the first FDA-approved anti-IgE antibody biosimilar referencing XOLAIR®. The 75 mg/0.5 mL, 150 mg/mL, and 300 mg/2 mL single-dose prefilled syringes are designated interchangeable with XOLAIR® for all indications based on data demonstrating therapeutic equivalence.
Indications: OMLYCLO® is indicated for:
- Moderate to severe persistent asthma in adults and children aged 6 years and older with specific allergen reactivity and inadequate control on inhaled corticosteroids.
- CRSwNP in adults 18 and older with insufficient response to nasal corticosteroids, as add-on maintenance therapy.
- IgE-mediated food allergy in adults and children aged 1 year and older to reduce the risk of allergic reactions, including anaphylaxis, with accidental exposure, alongside strict food allergen avoidance.
- CSU in adults and adolescents 12 years and older who remain symptomatic despite H1 antihistamines.
Important safety and usage notes:
- Warning: Anaphylaxis has been reported with omalizumab products, including OMLYCLO, and can occur after the first dose or after long-term use. Initiate therapy in a healthcare setting with observation and readiness to manage anaphylaxis. Consider patient suitability for self-administration on a case-by-case basis.
- Contraindication: Severe hypersensitivity to omalizumab or any OMLYCLO component.
- Other safety considerations include potential malignancies, lack of acute relief for asthma symptoms, the need to avoid abrupt corticosteroid withdrawal, eosinophilic conditions in certain contexts, and monitoring for parasitic infections in high-risk populations.
- Laboratory considerations: Omalizumab can alter total serum IgE levels; use of total IgE to guide dosing should be avoided for up to a year after discontinuation.
- Emergency treatment note: OMLYCLO is intended for maintenance therapy to reduce allergic reactions with allergen avoidance, not for emergency treatment of anaphylaxis.
Common adverse reactions vary by indication and age group, including injection-site reactions, headaches, nasal symptoms, and upper respiratory infections. The full prescribing information provides detailed safety data and is available via FDA resources.
Company and governance notes:
- Celltrion positions itself as a leader in biosimilars and innovative biologics, with a portfolio spanning immunology, oncology, hematology, ophthalmology, and endocrinology. The company highlights its ongoing commitment to improving patient access in the U.S.
- Celltrion USA, based in New Jersey, coordinates U.S. distribution and downstream support for OMLYCLO®, alongside other biosimilars and biologics.
Regulatory and forward-looking statements:
- The content includes statements about future expectations, plans, and potential market impacts. These forward-looking statements are subject to risks and uncertainties and are not guarantees of future performance. Readers should consider the associated risk factors disclosed in official filings.
Would this expanded dosing option influence your view on biosimilar interchangeability and patient access in the U.S.? Do you think more flexible dosing will change adherence and outcomes for allergic diseases, or might it raise new questions about long-term safety and cost? Share your thoughts in the comments.
